Delek Logistics Partners (NYSE:DKL) reported fourth-quarter net income of $47.3 million on Friday, marking a significant year-over-year increase from the $35.3 million recorded in late 2024.
Amneal Pharmaceuticals (NASDAQ:AMRX) posted fourth-quarter net revenue of $814 million on Friday, exceeding Wall Street’s consensus estimate of $806 million.
Mesoblast (NASDAQ:MESO) reported financial results for the first half of fiscal year 2026 on Friday, highlighting a decisive transition from a clinical-stage biotechnology firm to a commercial-scale operator.
Novavax (NASDAQ:NVAX) reported fourth-quarter financial results that caught Wall Street by surprise, swinging to a profit during a period analysts expected to remain firmly in the red.
Privia Health Group (NASDAQ:PRVA) today announced fiscal year 2025 results that landed at or above the high end of its previously issued guidance, bolstered by strong provider implementation and a disciplined focus on value-based care.
U.S. Physical Therapy (NYSE:USPH) reported a significant expansion in its 2025 financial performance, driven by robust organic growth and a steady cadence of clinic acquisitions.
Immunology pioneer argenx (NASDAQ:ARGX) delivered its first-ever year of operating profitability in 2025, powered by a massive commercial expansion of its flagship FcRn blocker, VYVGART.
Immuron (NASDAQ:IMRN), an Australian biopharmaceutical company developing hyper-immune bovine colostrum-derived therapies for gastrointestinal and infectious diseases, on Wednesday released its half-year fiscal 2026 results for the period ended December 31, 2025, alongside a strategic reset announcement.
LifeStance Health Group (NASDAQ:LFST) reported a decisive turn to profitability for fiscal year 2025, a landmark result for the nation’s largest provider of outpatient mental healthcare.
United Therapeutics (NASDAQ:UTHR) reported record-breaking financial results for fiscal year 2025 on Wednesday, marking the fourth consecutive year of all-time high revenues.
Recursion (NASDAQ:RXRX) reported fourth-quarter 2025 revenue of $35.5 million on Wednesday, significantly exceeding analyst estimates of $24.6 million.
Ionis Pharmaceuticals (NASDAQ:IONS) on Wednesday reported a net loss of $229 million for its fourth quarter ended December 31, 2025.
